• This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive , unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane. (ucsf.edu)
  • Clinically relevant improvements in survival have been attained by administering targeted therapy to the appropriate patient population: for example, the addition of trastuzumab to standard first-line chemotherapy in patients with human epidermal growth factor receptor-positive (HER2+) metastatic breast cancer 3 . (ersjournals.com)
  • The safety and efficacy of treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with pyrotinib. (news-medical.net)
  • In combination with docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (empr.com)
  • You have metastatic breast cancer (breast cancer that has spread beyond the original tumour) with high levels of HER2. (who.int)
  • BT-ON014 trade name] is also used in combination with medicines called aromatase inhibitors with patients with high levels of HER2 and hormone receptor-positive metastatic breast cancer (cancer that is sensitive to the presence of female sex hormones). (who.int)
  • Trastuzumab deruxtecan is already approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic breast cancer . (cancer.net)
  • Fig 1 Example of stratified medicines research, with translation from discovery of human epidermal growth factor receptor 2 (HER-2) status as a prognostic factor for metastatic breast cancer 5 to development of trastuzumab treatment and use in clinical practice. (bmj.com)
  • Olaparib is also approved by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and in other countries for treating women with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. (cancersa.org.au)
  • The US Food and Drug Administration (FDA) has approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for certain previously treated adults with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative, locally advanced or metastatic breast cancer . (medscape.com)
  • In fact, it not only yielded, in combination with chemotherapy, a significant improvement in progression-free and overall survivals, [ 2 ] but also allowed the evolution of the other HER2-targeted therapies, which currently represent the mainstay of treatment for locally advanced and metastatic breast cancer (mBC) with an HER2 amplification. (medscape.com)
  • HER-2/neu , also known as c-erbB-2/neu , is an oncogene located in chromosome 17 which encodes HER-2/neu, a transmembrane protein belonging to the EGFR family. (degruyter.com)
  • The discovery of epidermal growth factor receptor (EGFR) mutations in never-smokers has been the most relevant finding ever in non-small cell lung cancer. (aacrjournals.org)
  • Mechanisms of pathway activation other than mutation have been discovered in recent years, and include overexpression mediated by gene amplification or by amplification of a dinucleotide repeat in the EGFR promoter, mutation of an extracellular region on EGFR generating a mutant protein termed EGFRvIII, and enhanced signaling due to heterodimerization with other members of the EGFR family, particularly overexpression of HER2/HER3. (aacrjournals.org)
  • Although a number of studies have shown that patients with activating mutations in exons 18-21 of the epidermal growth factor receptor (EGFR) gene respond particularly well to gefitinib and erlotinib, a prospective, randomised study was needed to differentiate between the prognostic and predictive value of EGFR mutations. (ersjournals.com)
  • This review considers the current evidence linking biomarker profile to efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in advanced nonsmall cell lung cancer (NSCLC) and the clinical implications of recent findings. (ersjournals.com)
  • In NSCLC, activation of the EGFR/HER1 pathway results in a signalling cascade that promotes tumour growth and progression 6 . (ersjournals.com)
  • Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors of human epidermal growth factor receptor-2 (HER2) or epidermal growth factor receptor (EGFR) such as trastuzumab and lapatinib. (jcancer.org)
  • We investigated the effects of TAK-285, a novel, investigational, dual EGFR/HER2 inhibitor that has been shown to penetrate the CNS and has comparable inhibitory efficacy to lapatinib which is a known Pgp substrate. (jcancer.org)
  • In mouse and rat xenograft tumor models, TAK-285 showed antitumor activity against cancers that expressed HER2 or EGFR. (jcancer.org)
  • Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA) approval in combination with capecitabine for patients with advanced HER2+ breast cancer. (carcinogenesis.com)
  • Last, continuing HER2 blockade with trastuzumab in combination with several chemotherapeutic agents is preferable for subsequent lines of therapy, and the combinations of lapatinib [a dual kinase inhibitor that targets the intracellular domain of HER2 and epidermal growth factor receptor (EGFR)] with trastuzumab or capecitabine are reasonable treatment options for some patients. (medscape.com)
  • Due to the unobvious early symptoms and the influence of some adverse factors such as tumor heterogeneity and low immunogenicity, patients with advanced gastric cancer (AGC) cannot benefit significantly from treatments such as radical surgical resection, radiotherapy, chemotherapy, and targeted therapy. (frontiersin.org)
  • The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. (carcinogenesis.com)
  • The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional chemotherapy, using single or dual HER2-targeting drugs. (carcinogenesis.com)
  • We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
  • As chemotherapy affects cell division, tumors with high growth fractions (such as acute myelogenous leukemia and the aggressive lymphomas , including Hodgkin's disease ) are more sensitive to chemotherapy, as a larger proportion of the targeted cells are undergoing cell division at any time. (wikidoc.org)
  • Malignancies with slower growth rates, such as indolent lymphomas, tend to respond to chemotherapy much more modestly. (wikidoc.org)
  • The standard first treatment for people with HER2-positive stomach or esophageal cancer is the targeted therapy trastuzumab (Herceptin, Herceptin Hylecta, Herzuma, Ogivri, Ontruzant) given with chemotherapy. (cancer.net)
  • The biosimilar finds the HER2-positive cancer cells and then releases the chemotherapy to destroy them. (cancer.net)
  • [ 6 ] First, standard first line therapy for HER2-positive mBC is based on the combination of chemotherapy (namely a taxane) with a dual anti-HER2 blockade with trastuzumab and pertuzumab, a humanized monoclonal antibody targeting another HER2 epitope than trastuzumab. (medscape.com)
  • 10% and seems to be related to overexpression in tissue as well as to the most important prognostic factors: tumor size and nodal involvement. (degruyter.com)
  • Serial HER-2/neu determinations after surgery seem to be useful in the early diagnosis of recurrence, mainly in patients with HER-2/neu overexpression in tissue, but additional studies are necessary to confirm these results. (degruyter.com)
  • HER-2/neu sensitivity (proportion of patients with abnormal values) in patients with metastasis is around 40%-45%, with a clear relationship to tissue overexpression and to site (higher in visceral metastases) and number of metastases. (degruyter.com)
  • Amplification of the human epidermal growth factor receptor 2 ( HER2 ) gene and overexpression of the HER2 protein is found in 15%-20% of patients with gastric and gastroesophageal junction cancer. (wjgnet.com)
  • The degree of HER2 overexpression and amplification varies with the location of the carcinoma, with higher expression in the gastroesophageal and proximal parts compared to the distal parts of the stomach. (wjgnet.com)
  • Further, HER2 overexpression and amplification also seems to be related to the Lauren histological classification, with higher levels found in the intestinal phenotype compared to the diffuse and mixed types. (wjgnet.com)
  • The prognostic properties of HER2 overexpression and amplification are still under debate, but a large number of studies seem to indicate that HER2 is a negative prognostic factor. (wjgnet.com)
  • Patients with a strong overexpression of the HER2 protein (IHC3+) specifically benefited from the treatment, with a median overall survival of 17.9 mo. (wjgnet.com)
  • Test for HER2 protein overexpression and HER2 gene amplification using FDA-approved tests specific for breast cancer. (empr.com)
  • HER2 positive , which means the cancer has high levels of the HER2 protein or HER2 genes. (medlineplus.gov)
  • Cancers that have many copies of the HER2 gene or high levels of the HER2 protein are called "HER2-positive. (cancer.net)
  • The TNBC types are defined as breast cancers that lack expression of the oestrogen receptor (ER) and progesterone receptor (PR) and lack amplification of the human epidermal growth factor receptor 2 (HER-2) [ 4 - 6 ]. (hindawi.com)
  • Triple negative breast cancer (TNBC) is defined by the absence of expression for oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) which has limited targeted therapeutic options. (ecancer.org)
  • We performed a cost-minimization analysis to compare the cost of biomarker analysis for estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 status with immunohistochemistry versus STRAT4. (bvsalud.org)
  • In this study, we aimed to determine the pattern of immunohistochemical profiles of IDC using oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) and proliferative index (Ki-67) biomarkers in our tertiary healthcare facility in Uyo, Akwa Ibom State, Nigeria given the dearth of its data in our environment. (bvsalud.org)
  • The first study involving trastuzumab deruxtecan, called DESTINY Gastric-01 , was a phase II clinical trial of people with locally advanced or metastatic HER2-positive stomach cancer or esophageal cancer that was not stopped by treatment with trastuzumab. (cancer.net)
  • Approval of capivasertib was based on findings from the randomized, placebo-controlled, phase 3 CAPItello-291 trial, which involved 708 patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer, including 289 whose tumors had PIK3CA/AKT1/PTEN alterations. (medscape.com)
  • A HER2 amplification diagnostic test is now required in breast cancer before patients are treated with trastuzumab 2 . (ersjournals.com)
  • One type of breast cancer is identified by the human epidermal growth factor receptor 2 (HER2) gene amplification. (carcinogenesis.com)
  • Human epidermal receptor growth factor 2 ( HER2 , ERBB2 ) gene amplification occurs in about 15-20% of invasive breast cancers and is associated with biologically aggressive disease and poor overall survival in the absence of systemic therapy. (medscape.com)
  • Unlike the non-TNBC type of breast cancers, TNBC tumors belong to the biologically aggressive type of breast cancer and cannot be managed with targeted, endocrine, or HER2/neu-directed therapies [ 4 - 6 ]. (hindawi.com)
  • HR+ means that tumor cells have receptors for the hormones estrogen or progesterone, which can promote the growth of HR+ tumors. (cancer.gov)
  • This process, called angiogenesis, is essential for tumor growth and suggests that targeting RBM3 may be an extremely powerful tool against many and perhaps all solid tumors," Anant said. (sciencedaily.com)
  • Drugs affect "younger" tumors (i.e. more differentiated) more effectively, because mechanisms regulating cell growth are usually still preserved. (wikidoc.org)
  • With succeeding generations of tumor cells, differentiation is typically lost, growth becomes less regulated, and tumors become less responsive to most chemotherapeutic agents. (wikidoc.org)
  • Risk factor references Breast cancers are most often epithelial tumors involving the ducts or lobules. (msdmanuals.com)
  • Her-2/neu is an oncogene, which is a type of gene that can contribute to certain types of cancer. (medic8.com)
  • Normal cells have two copies of the Her-2/neu gene and low levels of Her-2 protein are produced on the surface of the cells. (medic8.com)
  • tumours that are associated with the Her-2/neu gene tend to be more aggressive and the outlook is generally not as positive. (medic8.com)
  • One such target of these novel therapies has been the human epidermal growth factor receptor 2 ( HER2 ) gene. (degruyter.com)
  • Unique in the approach to abolishing function of this gene coded receptor, it was the first target of new monoclonal antibody therapy targeting the extracellular receptor and now also a target of small molecule drugs against the intracellular tyrosine kinase domain. (degruyter.com)
  • But certain cancers have extra copies of the HER2 gene, which leads to too much HER2 protein on the cancer cells. (medlineplus.gov)
  • Some cancers, including some stomach and esophageal cancers, depend on a gene called human epidermal growth factor receptor 2 ( HER2 ) to grow. (cancer.net)
  • The HER2 gene makes HER2 proteins, which are found on certain cancer cells and contribute to cancer cell growth. (cancer.net)
  • State‑of‑the‑art research has indicated the retention of RUNX2 expression in a more invasive subtype of breast cancer, and in particular, triple‑negative breast cancer development and drug resistance are associated with estrogen receptor signaling pathways. (spandidos-publications.com)
  • BEBT-209 is under clinical development by Guangzhou BeBetter Medicine Technology and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). (pharmaceutical-technology.com)
  • According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. (pharmaceutical-technology.com)
  • Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. (wikipedia.org)
  • Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. (univaq.it)
  • Some types of cancer cells make larger than normal amounts of HER2, including certain cancers of the breast , stomach , and esophagus . (medlineplus.gov)
  • The cancer growing outside of your breast should be tested to see if it's HER2 positive, even if your breast tumor was already tested. (medlineplus.gov)
  • Several factors determine what type of breast cancer you have, your prognosis, and your treatment options. (mdanderson.org)
  • For instance, as reviewed by Li et al ( 3 ), triple-negative breast cancer (TNBC) may have worse cause-specific survival and overall survival than the non-TNBC counterpart in all stages and substages, regardless of influencing factors from univariate and multivariate analyses (e.g., tumor grade, age, ethnicity, surgery and radiation treatments). (spandidos-publications.com)
  • Your doctor can help you better understand how your specific circumstances will translate into breast cancer risk factors and symptoms. (healthline.com)
  • HER2+ means that tumor cells make high levels of a protein called HER2/neu, which has been shown to be associated with certain aggressive types of breast cancer. (cancer.gov)
  • The breast cancer subtype HR+/HER2- is the most common subtype with an age-adjusted rate of 87.2 new cases per 100,000 women, based on 2016-2020 cases. (cancer.gov)
  • This is a rate more than six times higher than the HR-/Her2- breast cancer rate of 13.2 and the HR+/HER2+ breast cancer rate of 12.6, and over 17 times higher than HR-/HER2+ breast cancer rate of 5.1. (cancer.gov)
  • While breast cancer subtype affects survival, stage at diagnosis may be the most powerful factor in determining survival outcome. (cancer.gov)
  • Additionally, 5-year relative survival for localized HR-/Her2- female breast cancer was 91.8 percent, but it dropped to 12.8 percent for distant disease. (cancer.gov)
  • The distribution of breast cancer subtypes among the female population varies by age, race, ethnicity, stage, and other factors. (cancer.gov)
  • Non-Hispanic White women have the highest rate of new cases of HR+/HER2− breast cancer. (cancer.gov)
  • Non-Hispanic Black women have the highest rate of new cases of HR−/HER2− breast cancer. (cancer.gov)
  • Androgen receptor (AR) is one of the predominant nuclear hormone receptors in invasive breast cancer and can be explored as a biomarker of response for targeted anti-androgen therapy, especially in the setting of triple negative breast cancer (TNBC). (ecancer.org)
  • TAK-285 was examined in a model of breast cancer brain metastasis using direct intracranial injection of BT-474-derived luciferase-expressing cells and showed greater inhibition of brain tumor growth compared to animals treated with lapatinib. (jcancer.org)
  • In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. (carcinogenesis.com)
  • This subtype accounts for approximately 20%-30% of invasive breast cancers, and until the discovery of effective anti-HER2 therapies ( first of which is trastuzumab), was associated with reduced disease-free survival (DFS), increased risk of metastases, and shorter overall survival (OS). (carcinogenesis.com)
  • June 5, 2019 About 20% of breast cancers make abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2). (sciencedaily.com)
  • You have early breast cancer, with high levels of HER2. (who.int)
  • In about two-thirds of breast cancer cases, the cancer is hormone receptor-positive . (healthline.com)
  • It's often used for advanced breast cancer, particularly when cancer is hormone receptor-negative. (healthline.com)
  • In human epidermal growth factor receptor 2 (HER2)-positive breast cancer , the cancer cells have too much of a growth protein called HER2. (healthline.com)
  • Being obese or overweight is a recognized breast cancer risk factor. (news-medical.net)
  • Moreover, a study found a significant positive association between human epidermal growth factor receptor 2 (HER2)+ and estrogen/progesterone (ER/PR)+ breast cancer and Western dietary trends. (news-medical.net)
  • this may be in part because they have a higher rate of triple-negative breast cancer (negative for estrogen and progesterone receptors and human epidermal growth factor receptor [HER2] oncogene), which has a poorer prognosis than other types. (msdmanuals.com)
  • Despite methodological differences, findings evidence that although IBC presents particular features (lower survival rate and worse prognostics than most types of breast cancer), very few studies examine its epidemiology and specific risk factors in depth and use any other therapeutic approaches than those commonly used for other breast cancer subtypes. (bvsalud.org)
  • [ 1 ] The synthesis of trastuzumab, a humanized monoclonal antibody targeting the extracellular domain of HER2, was a major leap forward in the treatment of this disease. (medscape.com)
  • however, such operational efficiencies are unlikely, and more laboratories are pursuing human epidermal growth factor receptor-2 analysis as targeted therapies become increasingly available. (bvsalud.org)
  • Cancers with large amounts of HER2 protein tend to grow quickly and spread to other parts of the body. (medlineplus.gov)
  • Certain medicines, called HER2 targeted therapy, can block or slow HER2 proteins and help control these cancers. (medlineplus.gov)
  • But these medicines won't help cancers that don't have high levels of HER2 proteins. (medlineplus.gov)
  • These cancers are likely to respond to HER2 targeted therapy. (medlineplus.gov)
  • HER2 tumor marker tests are mostly used to find out whether certain cancers are HER2 positive or negative. (medlineplus.gov)
  • Cancer of the pancreas, bladder, ovaries , or certain other cancers that may have high levels of HER2 which may be treated with medicines that target HER2. (medlineplus.gov)
  • Cancer occurs when changes called mutations take place in genes that regulate cell growth. (healthline.com)
  • The clinical utility of HER-2/neu in patients with advanced disease is mainly for therapeutic monitoring. (degruyter.com)
  • In this manuscript, we review the biology and clinical applications of HER2 as a biomarker of disease and as a therapeutic target. (degruyter.com)
  • The cell-surface receptor FcγRIIIa is crucial to the efficacy of therapeutic antibodies as well as the immune response. (bvsalud.org)
  • On this basis, the therapeutic approach of HER2-positive mBC has been totally reconfigured following a trilogy of randomized clinical trials published between 2012 and 2014. (medscape.com)
  • On the basis of the above-mentioned therapeutic sequence for HER2-positive mBC, trastuzumab emtansine currently represents the standard of care in second-line treatment. (medscape.com)
  • Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. (wikipedia.org)
  • Trastuzumab is a type of targeted therapy called a monoclonal antibody that works by targeting HER2 proteins on cancer cells to stop cancer growth. (cancer.net)
  • or for adjuvant treatment of patients with HER2-positive EBC at high risk of recurrence. (empr.com)
  • In fact, it is approved in many countries worldwide for the treatment of HER2 amplified mBC in patients who previously received trastuzumab and a taxane (separately or in combination), and who received previous therapy for mBC or developed disease recurrence within 6 months of completing adjuvant therapy. (medscape.com)
  • The ToGA trial must be characterized as a landmark in the treatment of gastric cancer and it has paved the way for a number of new HER2 targeted compounds such as pertuzumab, ado-trastuzumab emtansine, lapatinib, afatinib, and dacomitinib, which are currently undergoing phase II and III clinical testing. (wjgnet.com)
  • Second-line and subsequent therapy may involve single agents (eg, taxanes) or molecular therapy, such as ramucirumab to target vascular endothelial growth factor (VEGF) receptor or trastuzumab for metastatic adenocarcinoma that overexpresses HER2. (medscape.com)
  • However, newer options such as targeted therapy, anti-vascular endothelial growth factor (VEGF) receptor antibodies, and immunotherapy may have the potential to alter the standard of care. (cancernetwork.com)
  • This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. (nih.gov)
  • His subsequent research in the laboratory and clinic pioneered the universally adopted concept of anti-receptor therapy that targets key cell signaling pathways as a new form of cancer treatment. (wikipedia.org)
  • Antibody 225 (commercially known as Cetuximab, or Erbitux) against the receptor for epidermal growth factor was approved by the United States Food and Drug Administration for treatment of colon cancer in 2004 and for head and neck cancer in 2006. (wikipedia.org)
  • Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy (David A. Karnofsky Research Award Lecture). (wikipedia.org)
  • The usefulness of HER2 targeted therapy in gastric cancer was demonstrated in the ToGA trial, where HER2-positive patients with advanced gastric and gastroesophageal junction adenocarcinoma were randomized to receive 5-FU/capecitabine and cisplatin, either alone or in combination with trastuzumab. (wjgnet.com)
  • Overall, this review will discuss the current status of HER2 in gastric and gastroesophageal junction cancer and the future direction in relation to HER2 target therapy. (wjgnet.com)
  • HER2 negative , which means your cancer cells have little to no HER2 protein or a normal number of HER2 genes. (medlineplus.gov)
  • This type of cancer may grow more slowly than HER2-positive cancer. (medlineplus.gov)
  • HER2 targeted therapy will not work for this type of cancer, but other treatment options may help. (medlineplus.gov)
  • This information shows how fast cancer may grow and whether medicine to target HER2 proteins may be helpful. (medlineplus.gov)
  • Runt‑related transcription factor 2 (RUNX2), a pivotal transcription factor in mammary gland and bone development, has also been related to metastatic cancer and BCSCs. (spandidos-publications.com)
  • Compared with women with HR+/HER2− subtype (the most common subtype), those diagnosed with the other three subtypes were somewhat more likely to be younger, belong to minority groups, and be diagnosed with cancer at a later stage. (cancer.gov)
  • Researchers have now investigated the protein eIF4A3 and its role in the growth of cancer cells. (sciencedaily.com)
  • Every healthy cell produces a normal amount of HER2, but HER2 is produced 10 to 20 times more in a cancer cell," said Yehenew Agazie, an associate professor of biochemistry at the West Virginia University School of Medicine. (wvu.edu)
  • HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. (who.int)
  • Cancer is the uncontrolled growth of cells coupled with malignant behavior: invasion and metastasis . (wikidoc.org)
  • This means the hormones estrogen and progesterone are stimulating cancer cell growth. (healthline.com)
  • But these medications target and block the growth and spread of cancer by interfering with specific genes, proteins, or blood vessels. (healthline.com)
  • Targeted therapy uses drugs to target specific genes and proteins involved in the growth of cancer cells but limits damage to healthy cells. (cancer.net)
  • OBJECTIVES: To evaluate the expression of COX-2 and HER2 and determine their correlation with clinicopathologic parameters in surgically resected histologically diagnosed cases of colorectal cancer. (bvsalud.org)
  • CONCLUSION: This study detects a high COX-2 and low HER2 expression in colorectal cancer using immunohistochemistry,suggesting a possible role for COX-2 in CRC pathogenesis.This report should trigger further investigations of both markers vis-à-vis the management of CRC in our environment. (bvsalud.org)
  • As a consequence of the positive results of the ToGA trial, patients with advanced gastric or gastroesophageal junction adenocarcinoma are now routinely tested for HER2. (wjgnet.com)
  • Methods Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. (nih.gov)
  • These encouraging results deserve further investigation to determine their impact on overall survival in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. (nih.gov)
  • These results confirm that trastuzumab emtansine is an active treatment in previously treated HER2-positive mBC patients. (medscape.com)
  • The pattern of the association was quite homogeneous by BC subtypes based on hormone receptor status. (springer.com)
  • 10(-6) in the analyses by PR status, HER2 status, TN phenotype, morphologic subtypes, histological grade and nodal involvement. (lu.se)
  • HER2 genes have instructions for making the HER2 protein. (medlineplus.gov)
  • Normally, you have two HER2 genes in each cell, one from each parent. (medlineplus.gov)
  • [ 5 ] which are similar risk factors for (but not as strongly linked to) endometrial carcinoma . (medscape.com)
  • We aimed to examine the prevalence and pattern of co-occurring complications in this population, as well as the related risk factors. (cdc.gov)
  • We assessed sociodemographic and metabolic risk factors at baseline and at follow-up, and diabetes complications at follow-up. (cdc.gov)
  • A cluster analysis was done to identify unique clusters of participants based on demographic characteristics and metabolic risk factors. (cdc.gov)
  • Identification of individuals with adverse risk factors could enable targeted behavioural or medical interventions that reduce the likelihood of early development of lifelong diabetes-related morbidity. (cdc.gov)
  • So, HER2 tumor marker testing is necessary to find out if targeted therapy will be helpful. (medlineplus.gov)
  • When [BT-ON014 trade name] binds to HER2 it stops the growth of such cells and causes them to die. (who.int)
  • This means that other fast dividing cells such as those responsible for hair growth and for replacement of the intestinal epithelium (lining) are also often affected. (wikidoc.org)
  • Acute graft versus host disease (aGVHD) is a common complication following allogeneic hematopoietic stem cell transplantation (AHSCT) caused by cellular and inflammatory factors, including those arising from monocytes and dendritic cells as integral parts of the immune system. (magiran.com)